Cover Image
市場調查報告書

複雜性腹腔內感染疾病:開發平台評估

Complicated Intra-Abdominal Infections - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 251621
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
複雜性腹腔內感染疾病:開發平台評估 Complicated Intra-Abdominal Infections - Pipeline Review, H2 2014
出版日期: 2014年08月25日 內容資訊: 英文 74 Pages
簡介

腹腔內感染是腸內細菌侵食或增殖到管腔內臟器官壁或更多部位所造成的結果,擴大到侵食腹膜腔及腹腔內一般無菌狀態的其他部位時,便稱為「複雜性腹腔內感染疾病」。

本報告網羅全球複雜性腹腔內感染疾病治療藥的開發平台資訊,為您提供目前開發平台狀況和最新趨勢,藥物簡介,再加上主要企業及開發中的產品檢討等。

目錄

簡介

  • 分析範圍

複雜性腹腔內感染疾病概要

治療藥的開發

  • 複雜性腹腔內感染疾病開發中產品:概要
  • 複雜性腹腔內感染疾病開發中產品:比較分析

複雜性腹腔內感染疾病:正在開發的治療藥:各企業

複雜性腹腔內感染疾病:正在開發的治療藥:大學·研究機關別

複雜性腹腔內感染疾病:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

複雜性腹腔內感染疾病:開發中的產品:各企業

複雜性腹腔內感染疾病:開發中的產品:大學·研究機關別

複雜性腹腔內感染疾病:治療藥的開發企業

  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Melinta Therapeutics, Inc
  • Cubist Pharmaceuticals, Inc.
  • MerLion Pharmaceuticals Pte Ltd
  • Atox Bio Inc.
  • Tetraphase Pharmaceuticals Inc.
  • Biota Pharmaceuticals, Inc.

複雜性腹腔內感染疾病:治療藥的評估

  • 單劑治療藥
  • 組合
  • 標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (ceftolozane + tazobakutamu)
  • eravacycline
  • (sefutajijimu + avibactam)
  • delafloxacin
  • MK-7655
  • AB-103
  • GyrB/ParE抗生劑
  • finafloxacin
    • 產品概要
    • 作用機制
    • R&D的進展

最新的開發平台趨勢

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5403IDB

Summary

Global Markets Direct's, 'Complicated Intra-Abdominal Infections - Pipeline Review, H2 2014', provides an overview of the Complicated Intra-Abdominal Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Complicated Intra-Abdominal Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Intra-Abdominal Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Complicated Intra-Abdominal Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Complicated Intra-Abdominal Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Complicated Intra-Abdominal Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Complicated Intra-Abdominal Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Complicated Intra-Abdominal Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Complicated Intra-Abdominal Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Complicated Intra-Abdominal Infections Overview
  • Therapeutics Development
    • Pipeline Products for Complicated Intra-Abdominal Infections - Overview
    • Pipeline Products for Complicated Intra-Abdominal Infections - Comparative Analysis
  • Complicated Intra-Abdominal Infections - Therapeutics under Development by Companies
  • Complicated Intra-Abdominal Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Complicated Intra-Abdominal Infections - Products under Development by Companies
  • Complicated Intra-Abdominal Infections - Companies Involved in Therapeutics Development
    • AstraZeneca PLC
    • Merck & Co., Inc.
    • Melinta Therapeutics, Inc
    • Cubist Pharmaceuticals, Inc.
    • MerLion Pharmaceuticals Pte Ltd
    • Nabriva Therapeutics AG
    • Atox Bio Inc.
    • Tetraphase Pharmaceuticals Inc.
  • Complicated Intra-Abdominal Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (ceftolozane + tazobactam) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eravacycline - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (ceftazidime + avibactam) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • delafloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MK-7655 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AB-103 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit 50S RNA for Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KBP-7072 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • finafloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Complicated Intra-Abdominal Infections - Recent Pipeline Updates
  • Complicated Intra-Abdominal Infections - Dormant Projects
  • Complicated Intra-Abdominal Infections - Discontinued Products
  • Complicated Intra-Abdominal Infections - Product Development Milestones
    • Featured News & Press Releases
      • Jul 28, 2014: Tetraphase Pharmaceuticals Completes Enrollment of IGNITE 1 Eravacycline Phase 3 Clinical Trial in Complicated Intra-abdominal Infections
      • Mar 20, 2014: Tetraphase Pharmaceuticals Provides Update on Clinical Progress of Phase 3 Lead Antibiotic Candidate Eravacycline
      • Dec 16, 2013: Cubist Announces Positive Top-Line Results from Phase 3 Trial of Ceftolozane/Tazobactam in Intra-Abdominal Infections
      • Sep 12, 2013: Ceftazidime/avibactam Combination Receives Qualified Infectious Disease Product (QIDP) Designation from FDA
      • Sep 04, 2013: Tetraphase to Present Data at ICAAC Supporting Its Lead Antibiotic Candidate Eravacycline's Effectiveness against Multi-drug Resistant Pathogens
      • Sep 03, 2013: Tetraphase Doses First Patient in Phase 3 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections
      • Jul 15, 2013: FDA Grants QIDP Designation to Eravacycline, Tetraphase's Lead Antibiotic Product Candidate
      • May 07, 2013: Cubist's Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation
      • Jan 07, 2013: Cubist Pharma Provides Update On Infectious Disease Drug Candidate, Ceftolozane
      • Dec 06, 2012: Cubist Pharma's Antibiotic Candidate Ceftolozane Obtains QIDP Designation From FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Complicated Intra-Abdominal Infections, H2 2014
  • Number of Products under Development for Complicated Intra-Abdominal Infections - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Complicated Intra-Abdominal Infections - Pipeline by AstraZeneca PLC, H2 2014
  • Complicated Intra-Abdominal Infections - Pipeline by Merck & Co., Inc., H2 2014
  • Complicated Intra-Abdominal Infections - Pipeline by Melinta Therapeutics, Inc, H2 2014
  • Complicated Intra-Abdominal Infections - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014
  • Complicated Intra-Abdominal Infections - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2014
  • Complicated Intra-Abdominal Infections - Pipeline by Nabriva Therapeutics AG, H2 2014
  • Complicated Intra-Abdominal Infections - Pipeline by Atox Bio Inc., H2 2014
  • Complicated Intra-Abdominal Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Assessment by Combination Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Complicated Intra-Abdominal Infections Therapeutics - Recent Pipeline Updates, H2 2014
  • Complicated Intra-Abdominal Infections - Dormant Projects, H2 2014
  • Complicated Intra-Abdominal Infections - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Complicated Intra-Abdominal Infections, H2 2014
  • Number of Products under Development for Complicated Intra-Abdominal Infections - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Late Stage Products, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Assessment by Combination Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top